<DOC>
	<DOC>NCT00414089</DOC>
	<brief_summary>The purpose of this study is to see how well Zevalin works in the treatment of low grade indolent B-cell lymphoma when given to patients who have not had any previous treatment for their lymphoma and who otherwise would be followed on a "watch &amp; wait" policy.</brief_summary>
	<brief_title>Efficacy and Safety of Treatment With a Single Dose of 90Y-ibritumomab Tiuxetan in Patients With Low Tumor Burden Untreated or Indolent NHL</brief_title>
	<detailed_description />
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Antibodies, Monoclonal</mesh_term>
	<criteria>histologically confirmed indolent lymphoma including: follicular grade 1 or 2 small lymphocytic marginal zone (nodal) marginal zone (splenic) mucosa associated lymphoid tissue (MALT) no evidence of transformation Stage III or IV disease No prior therapy involvement by less than 25% of bone marrow on assessment of trephine biopsy absolute lymphocyte count ≤ x 109/L platelets ≥ 150 x 109/L hemoglobin ≥ 100g/L absolute neutrophil count ≥ 1.5 x 109/L at least one bidimensionally measurable lesion at least 2cm by CT scanning any other anticancer treatment for NHL prior radiation therapy prior myeloablative therapy (bone marrow or peripheral blood stem cell transplant) no other malignancy within the past 10 years except adequately treated nonmelanoma skin tumors or carcinoma in situ of the cervix presence of central nervous system lymphoma patients known to be HIV positive patients with known seropositivity for Hepatitis C virus, Hepatitis B virus or other active infection uncontrolled by treatment patients with abnormal liver function: total bilirubin &gt; 1.5X ULN or ALT &gt; 2.5X ULN patients with abnormal renal function: serum creatinine &gt; 2.5X ULN known hypersensitivity to murine antibodies or proteins immunotherapy during the preceding 6 months (including monoclonal antibodies, interleukins, interferon)</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2007</verification_date>
</DOC>